Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease

• US 20020009445A1
• Filed: 06/19/2001
• Published: 01/24/2002
• Est. Priority Date: 07/12/2000
• Status: Abandoned Application

• Current Assignee: Richard Dodel, Yansheng Du
• Original Assignee: Richard Dodel, Yansheng Du
• Inventors: Du, Yansheng, Dodel, Richard
• Application Number:
  US09/884,408
• Publication Number:
  US 20020009445A1
• Time in Patent Office: Days
• US Class Current: 424/142.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/21 from primates, e.g. man

Abstract

The present invention provides according to the first aspect thereof a human anti-β-amyloid antibody obtained by purification from a human IgG-containing bodyfluid by Aβ-affinity chromatography. In a second aspect the invention provides a method of purification of an anti-Aβ-amyloid antibody, said method comprising the steps of obtaining a human IgG-containing bodyfluid, subjecting the bodyfluid obtained to an Aβ-affinity chromatography, and recovering the purified anti-Aβ antibody from the chromatography medium. Finally the invention provides for use of the above anti-Aβ antibody for diagnosing and/or treating amyloid associated diseases, especially Alzheimer'"'"'s disease and for a pharmaceutical composition comprising said antibody for treatment of Alzheimer'"'"'s disease.

Claims

1. A human anti-Aβ

-amyloid antibody obtained by purification from a human IgG-containing bodyfluid by Aβ

-affinity chromatography.

2. Human anti-Aβ

-amyloid antibody of claim 1, characterized in that it belongs to the class of immunoglobulines G (IgG) and does not recognize Aβ

_40-1, neuropeptide F, neuropeptide Y, and Amylin, and specifically recognizes one or more of Aβ

_1-40,Aβ

_1-42 Aβ

_25-35.

6. Use of an anti-Aβ

-amyloid antibody according to claims 1 or 2 for treating amyloid associated diseases, especially Alzheimer'"'"'s disease and primary and secondary amyloidoses.

7. Use of an anti-Aβ

-amyloid antibody according to claims 1 or 2 for diagnosis of amyloid associated diseases, especially Alzheimer'"'"'s disease and primary and secondary amyloidoses.

9. Pharmaceutical composition comprising an anti-Aβ

-amyloid antibody according to claims 1 or 2.

3. A method of purification of an anti-Aβ

-amyloid antibody comprising the steps of

(i) obtaining a human IgG-containing bodyfluid,

(ii) subjecting the bodyfluid obtained to an Aβ

-affinity chromatography, and

(iii) recovering the purified anti-Aβ

antibody.

4. The method of claim 3 wherein the IgG-containing bodyfluid is a cerebrospinal fluid, plasma or urine obtained from one or more human beings (pooled samples).

5. The method of claim 3, wherein A-affinity chromatography is carried out by an Aβ

-affinity column, obtained by conjugating Aβ

_1-40 onto Sepharose 4B, elution with elute buffer at pH 1.5 to 2.5 at 4°

C. using an FPLC system.

8. Use of an IgG containing, preferably IgG enriched fluid for treatment of amyloid associated diseases, especially Alzheimer'"'"'s disease.